In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and Div Dubey, M.B.B.S., a neurologist and co-director of the Clinical Neuroimmunology Laboratory at Mayo Clinic, explore the topic of peripheral neuropathy. Their discussion covers:

• The high prevalence of peripheral neuropathy and why early diagnosis is important. 
• The complexities involved in diagnosing the condition.
• Symptoms that should prompt clinicians to order advanced testing early in the diagnostic process.
• How algorithms are enhancing the use of testing to complement other diagnostic tools.
• Ongoing discovery related to specific antibodies associated with neuropathies.

Learn more in our e-book, "Peripheral neuropathy: Cutting through diagnostic dissonance with an algorithmic approach."

Joseph Yao, M.D., explains how Mayo Clinic Laboratories' new quantitative assay (Mayo ID: ADVQU) goes beyond qualitative testing to evaluate transplant patients for adenovirus infection. Adenovirus can cause life-threatening disease in immunocompromised transplant patients, especially children.

(01:14)
Could you give us a brief overview of this assay?

(02:06)
Can you explain the differences of the qualitative and quantitative methods and why we made the change to a quantitative adenovirus method?

(04:00)
When is this test typically ordered for transplant patients? Is it used throughout their treatment?

(06:56)

Could an immunocompromised person be unknowingly infected?

(07:31)

Is our quantitative method approved for pediatric patients?

(08:00)

How are the test results used to treat patients?

(10:36)

What other infections might providers consider alongside adeovirus?

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, discuss global trends in diagnostic manufacturing and their implications for laboratory professionals. Topics include: 

• Emerging innovations in mass spectrometry, next-generation sequencing, automation, and artificial intelligence. 
• Fierce competition in the global manufacturing landscape as new companies enter the market. 
• Geopolitical dynamics influencing where innovations are deployed. 
• Why laboratory professionals need to drive innovation implementation to maximize benefits for clinicians and their patients.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the value laboratories deliver for their entire health system. They cover how laboratories impact:

• Growth in revenue
• Growth in lab charges
• Growth in ancillary services
• Hospital length of stay
• Control over expenses

You can also find more in-depth information on this topic in “Maximizing your health system’s financial performance,” a white paper with data-driven ways laboratories support their organizations. 

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss tick-borne diseases. They cover:

• Different diseases patients can get from ticks. 
• Disease prevention, including Dr. Pritt’s A through Z flash cards with tips for people to protect themselves from infectious insects.
• Laboratory medicine’s valuable role in testing and educating providers to diagnose patients quickly and accurately.
• Clinical areas most likely to encounter patients with tick-borne diseases.
• Reliable sources for details about the prevalence of different diseases around the country (e.g., U.S. Centers for Disease Control and Prevention (CDC) and Mayo Clinic Laboratories).

In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by Russ Lebovitz, M.D., Ph.D., CEO and co-founder of Amprion. They discuss their strategic collaboration and the innovative SAAmplify™–αSYN (CSF) test. They covered: 

• Details about how the cerebrospinal fluid biomarker test (Mayo ID: ASYNC) benefits patients exhibiting signs and symptoms of clinically uncertain cognitive decline or clinically uncertain Parkinsonian syndromes.
• Groundbreaking science on proteins that Amprion leveraged to create a solution that meaningfully impacts patient care and provides value to clinicians.
• Information physicians receive from the test, and when they should consider ordering it for their patients. 
• Opportunities to change diagnostic journeys by providing accurate, early diagnosis with SAAmplify–αSYN. 

Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' SPAS test identifies the form of arsenic present in patients with arsenic exposure. That information is important for determining the potential level of harm and for removing the patient from the arsenic source to ease symptoms and prevent cancer risk.

(00:33)
Do you mind telling us a little bit about yourself and your background?

(01:45)
Could you please provide us with an overview of arsenic, how people get exposed, and the laboratory testing for arsenic and arsenic speciation?

(05:25)
Which patients should have this testing, and when should it be performed?

(06:57)
What alternative test options are available, and how does testing at Mayo Clinic compare?

(08:37)

How are the results used in patient care?

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the recent court judgment on the U.S. Food and Drug Administration’s (FDA) oversight of lab-developed tests (LDT). They covered: 
 

• Details about the ruling to vacate the FDA’s rule on LDT oversight. 
• What LDT oversight might look like in the future. 
• How the laboratory medicine industry can help create an oversight approach that is positive for both patients and innovation. 

Jessica Wright, Pharm.D., BCACP, explains how Mayo Clinic Laboratories' 3A5Q test helps determine initial tacrolimus doses for individuals after non-liver organ transplants. Optimal tacrolimus levels are one of the important factors in survival of the transplanted organ.

(00:32)
Could you provide us a with little bit about your background and yourself?

(03:45)
Will you please provide a brief overview of Mayo test 3A5Q?

(06:56)
Which patients should have this testing, and when should it be performed?

(08:15)
 What alternative or complementary tests should be considered?

(09:25)

How are the results used in patient care?

(10:38)

Will you help the audience understand the significance of monitoring tacrolimus levels for transplant rejection?

(12:53)

What alleles are included in this test?

In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, invited Min-Han Tan, M.B.B.S., FRCP, Ph.D., founding CEO and medical director of Lucence, to discuss liquid biopsy cancer testing. Mayo Clinic Laboratories and Lucence recently announced a collaboration to expand access to this cutting-edge cancer test that is designed to detect clinically relevant biomarkers in ctDNA and ctRNA.

During their conversation, Dr. Morice and Dr. Tan explore:

• Inspiration for developing the liquid biopsy.
• Features that differentiate LiquidHALLMARK® from existing cancer tests.
• Patients who will benefit from the test and how an oncologist might use the results.
• The future potential of liquid biopsy advancements.